Adapting Clinical Practice of Thrombolysis for Acute Ischemic Stroke Beyond 4.5 Hours: A Review of the Literature
- PMID: 34464927
- DOI: 10.1016/j.jstrokecerebrovasdis.2021.106059
Adapting Clinical Practice of Thrombolysis for Acute Ischemic Stroke Beyond 4.5 Hours: A Review of the Literature
Abstract
Several clinical trials have demonstrated that advanced neuroimaging can select patients for recanalization therapy in an extended time window. The favorable functional outcomes and safety profile of these studies have led to the incorporation of neuroimaging in endovascular treatment guidelines, and most recently, also extended to decision making on thrombolysis. Two randomized clinical trials have demonstrated that patients who are not amenable to endovascular thrombectomy within 4.5 hours from symptoms discovery or beyond 4.5 hours from the last-known-well time may also be safely treated with intravenous thrombolysis and have a clinical benefit above the risk of safety concerns. With the growing aging population, increased stroke incidence in the young, and the impact of evolving medical practice, healthcare and stroke systems of care need to adapt continuously to provide evidence-based care efficiently. Therefore, understanding and incorporating appropriate screening strategies is critical for the prompt recognition of potentially eligible patients for extended-window intravenous thrombolysis. Here we review the clinical trial evidence for thrombolysis for acute ischemic stroke in the extended time window and provide a review of new enrolling clinical trials that include thrombolysis intervention beyond the 4.5 hour window.
Keywords: Acute Ischemic stroke; Extended time window; Intravenous thrombolysis; Wake-up stroke; stroke systems of care.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest Ona Wu: Consulting: Penumbra, Inc; Advisory Board Member: Genentech, Inc; Co-inventor of a patent on “Delay-compensated calculation of tissue blood flow,” US Patent 7,512,435. March 31, 2009, and the patent has been licensed to General Electric, Siemens, Imaging Biometrics, and Olea Medical. All other authors report no conflicts of interest to report.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical